We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

75 hedge funds and large institutions have $264M invested in BioCryst Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $6.94M | Put options by funds: $3.7M

61% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 18

21% more capital invested

Capital invested by funds: $217M → $264M (+$46.2M)

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

3% more funds holding

Funds holding: 73 → 75 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
75
Holders Change
+2
Holders Change %
+2.74%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
15
Increased
29
Reduced
18
Closed
13
Calls
$6.94M
Puts
$3.7M
Net Calls
+$3.24M
Net Calls Change
+$1.3M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$16.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.7M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$10.2M
4
BFA
BlackRock Fund Advisors
California
+$4.35M
5
Morgan Stanley
Morgan Stanley
New York
+$2.9M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$9.48M
2
DM
Deerfield Management
New York
-$4.84M
3
TC
TFS Capital
Pennsylvania
-$4.53M
4
BIM
Bogle Investment Management
Massachusetts
-$2.81M
5
VM
VHCP Management
New York
-$2.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$50.9M – – –
Wellington Management Group
2
Wellington Management Group
Massachusetts
$36.4M +$13.7M +2,159,640 +82%
RCM
3
RA Capital Management
Massachusetts
$33M -$9.48M -1,497,244 -26%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$19.8M +$16.3M +2,576,200 +9,368%
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$18.5M +$10.2M +1,617,669 +197%
VM
6
VHCP Management
New York
$13.3M -$2.7M -426,300 -20%
Vanguard Group
7
Vanguard Group
Pennsylvania
$13.3M +$517K +81,642 +5%
TGHSA
8
TPG Group Holdings (SBS) Advisors
Texas
$8.83M – – –
BIT
9
BlackRock Institutional Trust
California
$8.6M -$212K -33,541 -3%
DM
10
Deerfield Management
New York
$6.6M -$4.84M -763,790 -47%
BFA
11
BlackRock Fund Advisors
California
$6.34M +$4.35M +686,454 +463%
Millennium Management
12
Millennium Management
New York
$4.89M +$2.52M +398,163 +162%
Morgan Stanley
13
Morgan Stanley
New York
$4.05M +$2.9M +458,179 +612%
QF
14
QVT Financial
New York
$4M +$2.02M +318,700 +154%
TC
15
TFS Capital
Pennsylvania
$3.8M -$4.53M -714,636 -59%
Jennison Associates
16
Jennison Associates
New York
$2.72M -$587K -92,648 -21%
Connor, Clark & Lunn Investment Management (CC&L)
17
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.56M +$2.01M +316,878 New
SGAM
18
Smith Group Asset Management
Texas
$2.22M -$10.2K -1,613 -0.5%
CAM
19
Cormorant Asset Management
Massachusetts
$2.04M +$1.7M +268,000 New
VAM
20
Visium Asset Management
New York
$1.78M -$12.7K -2,000 -0.8%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$1.68M +$102K +16,109 +8%
PA
22
Perceptive Advisors
New York
$1.5M +$43.8K +6,912 +4%
California Public Employees Retirement System
23
California Public Employees Retirement System
California
$1.09M – – –
FSA
24
Franklin Street Advisors
North Carolina
$1.06M – – –
CS
25
Credit Suisse
Switzerland
$1.04M +$782K +123,514 +897%
1
2 3 4

BCRX Hedge Fund Activity: Q4 2013 in Review

75 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2013, worth a combined $264M — up 21% from $217M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new BCRX positions and 13 closed out — a net gain of 2 holders — while 29 added to existing stakes and 18 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $16.3M. The largest seller was RA Capital Management, cutting an estimated $9.48M.

  • 75 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2013, up from 73 in Q3 2013.
  • Funds reported $264M of BioCryst Pharmaceuticals stock for Q4 2013, up 21% quarter-over-quarter.
  • 15 funds opened new BioCryst Pharmaceuticals positions in Q4 2013 and 13 closed out, a net change of +2 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q4 2013 was Fidelity Investments, an estimated $16.3M added.
  • The largest BioCryst Pharmaceuticals seller in Q4 2013 was RA Capital Management, an estimated $9.48M sold.

Based on aggregated 13F filings for Q4 2013.